An open-label study on the short-term effects of a novel EFSA-compliant nutraceutical combination in mild-to-moderate hypercholesterolemia

Document Type : Short communication


1 Studio Minoretti, Oggiono (LC), Italy

2 Department of Environment, Earth and Physical Sciences, University of Siena, Siena, Italy

3 2E Science, Robbio (PV), Italy


Objective: Recently, the European Food Safety Authority (EFSA) has recommended to limit the use of total monacolins in red yeast rice (RYR) products to a dose <3 mg/day. However, data concerning the lipid lowering efficacy of the reduced dosage remain limited. A monacolin dose reduced due to safety issues may be expected to be less effective as a lipid lowering strategy and, for this reason, nutraceutical combinations with other active compounds may offer a viable solution as they can act synergistically through different mechanisms.
Materials and Methods: This 8-week open-label study was designed to investigate the safety and efficacy of a novel ESFA-compliant lipid lowering nutraceutical combination (Colestarmony Plus®; containing total monacolins from RYR at a dose of 2.9 mg/day, a highly bioavailable berberine formulation, and pomegranate extract) in subjects (n=40) with mild-to-moderate hypercholesterolemia and no history of cardiovascular disease.
Results: After 8 weeks of supplementation, Colestarmony Plus® significantly reduced total cholesterol (−10.4%, p<0.05), low-density lipoprotein cholesterol (−14.8%, p<0.05), oxidized low-density lipoprotein cholesterol (−12.0%, p<0.05), and high-sensitivity C-reactive protein (−14.0%, p<0.05) compared with baseline values. A subgroup of 22 patients underwent measurements of flow-mediated dilation, with values increasing by 18.0% at 8 weeks with respect to baseline (p<0.05). The supplement was generally well-tolerated.
Conclusion: Our short-term results indicate that the tested ESFA-compliant nutraceutical is effective in a primary prevention setting, even by providing only <3 mg/day of monacolins.


Alaei Z, Doudi M, Setorki M. 2020. The
protective role of Kombucha extract on the
normal intestinal microflora, highcholesterol diet caused
hypercholesterolemia, and histological
structures changes in New Zealand white
rabbits. Avicenna J Phytomed, 10: 604-
Allijn IE, Czarny BMS, Wang X, Chong SY,
Weiler M, da Silva AE, Metselaar JM,
Lam CSP, Pastorin G, de Kleijn DPV,
Storm G, Wang JW, Schiffelers RM. 2017.
Liposome encapsulated berberine
treatment attenuates cardiac dysfunction
after myocardial infarction. J Control
Release, 247: 127-133.
Banach M, Bruckert E, Descamps OS, Ellegård
L, Ezhov M, Föger B, Fras Z, Kovanen PT,
Latkovskis G, März W, Panagiotakos DB,
Paragh G, Pella D, Pirillo A, Poli A, Reiner
Ž, Silbernagel G, Viigimaa M, Vrablík M,
Catapano AL. 2019. The role of red yeast
rice (RYR) supplementation in plasma
cholesterol control: A review and expert
opinion. Atheroscler Suppl, 39: e1-e8.
Biagi M, Minoretti P, Bertona M, Emanuele E.
2018. Effects of a nutraceutical
combination of fermented red rice,
liposomal berberine, and curcumin on lipid
and inflammatory parameters in patients
with mild-to-moderate
hypercholesterolemia: an 8-week, openlabel, single-arm pilot study. Arch Med Sci
Atheroscler Dis, 3: e137-e141.
Brown AS, Watson KE. 2018. Statin
intolerance. Rev Cardiovasc Med, 19: S9-
Chou R, Dana T, Blazina I, Daeges M, Jeanne
TL. 2016. Statins for prevention of
cardiovascular disease in adults: evidence
report and systematic review for the US
preventive services task force. JAMA,
316: 2008-2024.
Cicero AFG, Fogacci F, Banach M. 2019. Red
yeast rice for hypercholesterolemia.
Methodist Debakey Cardiovasc J, 15: 192-
D’Addato S, Scandiani L, Mombelli G, Focanti
F, Pelacchi F, Salvatori E, Di Loreto G,
Comandini A, Maffioli P, Derosa G. 2017.
Effect of a food supplement containing
berberine, monacolin K, hydroxytyrosol
and coenzyme Q10 on lipid levels: a
randomized, double-blind, placebo
controlled study. Drug Des Devel Ther,
11: 1585-1592.
Dougnon TV, Bankolé HS, Klotoé JR, Sènou
M, Fah L, Koudokpon H, Akpovi C,
Dougnon TJ, Addo P, Loko F, Boko M.
2014. Treatment of hypercholesterolemia:
screening of Solanum macrocarpon Linn
(Solanaceae) as a medicinal plant in Benin.
Avicenna J Phytomed, 4: 160-169.
Fatahian A, Haftcheshmeh SM, Azhdari S,
Farshchi HK, Nikfar B, Momtazi-Borojeni
AA. 2020. Promising anti-atherosclerotic
effect of berberine: evidence from in vitro,
in vivo, and clinical studies. Rev Physiol
Biochem Pharmacol, 178: 83-110.
Gerards MC, Terlou RJ, Yu H, Koks CH,
Gerdes VE. 2015. Traditional Chinese
lipid-lowering agent red yeast rice results
in significant LDL reduction but safety is
uncertain - a systematic review and metaanalysis. Atherosclerosis, 240: 415-423.
Ghannadi A, Movahedian A, Jannesary Z.
2015. Hypocholesterolemic effects of
Balangu (Lallemantia royleana) seeds in
the rabbits fed on a cholesterol-containing
diet. Avicenna J Phytomed, 5: 167-173.
Kazi DS, Penko JM, Bibbins-Domingo K.
2017. Statins for primary prevention of
cardiovascular disease: review of evidence
and recommendations for clinical practice.
Med Clin North Am, 101: 689-699.
Liu CS, Zheng YR, Zhang YF, Long XY. 2016.
Research progress on berberine with a
special focus on its oral bioavailability.
Fitoterapia, 109: 274-282.
Nannoni G, Volterrani G, Mattarocci A,
Minoretti P, Emanuele E. 2020.
Comparative efficacy and safety of
Verbascox® - a proprietary herbal extract
capable of inhibiting human
cyclooxygenase-2 - and celecoxib for knee
osteoarthritis. Drug Discov Ther, 14: 129-
Poli A, Barbagallo CM, Cicero AFG, Corsini
A, Manzato E, Trimarco B, Bernini F,
Visioli F, Bianchi A, Canzone G, Crescini
C, de Kreutzenberg S, Ferrara N,
Gambacciani M, Ghiselli A, Lubrano C,
Marelli G, Marrocco W, Montemurro V,
Parretti D, Pedretti R, Perticone F, Stella
R, Marangoni F. 2018. Nutraceuticals and
functional foods for the control of plasma
cholesterol levels. An intersociety position
paper. Pharmacol Res, 134: 51-60.
A novel EFSA-compliant nutraceutical
AJP, Vol. 12, No. 6, Nov-Dec 2022 565
Thijssen DHJ, Bruno RM, van Mil ACCM,
Holder SM, Faita F, Greyling A, Zock PL,
Taddei S, Deanfield JE, Luscher T, Green
DJ, Ghiadoni L. 2019. Expert consensus
and evidence-based recommendations for
the assessment of flow-mediated dilation
in humans. Eur Heart J, 40: 2534-2547.
Wang D, Özen C, Abu-Reidah IM, Chigurupati
S, Patra JK, Horbanczuk JO, Jóźwik A,
Tzvetkov NT, Uhrin P, Atanasov AG.
2018. Vasculoprotective effects of
pomegranate (Punica granatum L.). Front
Pharmacol, 9: 544.
Xiong Z, Cao X, Wen Q, Chen Z, Cheng Z,
Huang X, Zhang Y, Long C, Zhang Y,
Huang Z. 2019. An overview of the
bioactivity of monacolin K / lovastatin.
Food Chem Toxicol, 131: 110585.